Literature DB >> 3940619

Two years of high-dose cyclophosphamide and 5-fluorouracil followed by surgery after 3 months for acute inflammatory breast carcinomas. A phase II study of 25 cases with a median follow-up of 35 months.

L Israël, J L Breau, J F Morere.   

Abstract

Twenty-five consecutive cases of inflammatory breast carcinoma were treated with high-dose cyclophosphamide and 5-fluorouracil in 5-day courses every 3 weeks for 2 years, with total mastectomy performed after the third course. The toxicity was high but acceptable in 24 of the patients, provided the doses were decreased. Tumor was found at surgery in all 24 patients, and the lymph nodes were involved in 19 of 24 cases. The median follow-up was 35 months (range, 16-76 months). Thirteen relapses were observed, three of which were exclusively locoregional. The median disease-free survival was 46 months. The expected median survival is greater than 6 years. Six patients were treated with radiotherapy for regional recurrences. The good results obtained with this severe form of the disease confirm: that chemotherapy is highly effective in primary tumors and that initial radiotherapy is not necessary in the management of this disease.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3940619     DOI: 10.1002/1097-0142(19860101)57:1<24::aid-cncr2820570107>3.0.co;2-2

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  4 in total

Review 1.  Management of inflammatory breast cancer.

Authors:  S E Singletary; F C Ames; A U Buzdar
Journal:  World J Surg       Date:  1994 Jan-Feb       Impact factor: 3.352

2.  The management of locally advanced breast cancer.

Authors:  R D Rubens
Journal:  Br J Cancer       Date:  1992-02       Impact factor: 7.640

3.  First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial).

Authors:  P Viens; T Palangié; M Janvier; M Fabbro; H Roché; T Delozier; J P Labat; C Linassier; B Audhuy; F Feuilhade; B Costa; R Delva; H Cure; F Rousseau; A Guillot; M Mousseau; J M Ferrero; V J Bardou; J Jacquemier; P Pouillart
Journal:  Br J Cancer       Date:  1999-10       Impact factor: 7.640

4.  The Centre H. Becquerel studies in inflammatory non metastatic breast cancer. Combined modality approach in 178 patients.

Authors:  B Chevallier; P Bastit; Y Graic; J F Menard; J P Dauce; J P Julien; B Clavier; A Kunlin; J D'Anjou
Journal:  Br J Cancer       Date:  1993-03       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.